What is HC Wainwright's Forecast for Oculis Q1 Earnings?

Oculis Holding AG (NASDAQ:OCS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Oculis in a report issued on Monday, May 12th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.46) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis' Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.40) EPS.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.27). The business had revenue of $0.32 million during the quarter, compared to the consensus estimate of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Several other analysts have also recently issued reports on OCS. Chardan Capital upped their price objective on Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday. Robert W. Baird upped their price target on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research note on Thursday, March 13th.

Oculis Stock Down 5.3%

OCS opened at $17.60 on Tuesday. Oculis has a 52 week low of $10.79 and a 52 week high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $18.01 and a two-hundred day simple moving average of $18.40. The company has a market capitalization of $768.45 million, a PE ratio of -9.12 and a beta of 0.27.

Hedge Funds Weigh In On Oculis

Large investors have recently modified their holdings of the stock. abrdn plc boosted its stake in shares of Oculis by 23.0% during the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock worth $17,150,000 after purchasing an additional 188,871 shares during the period. Citadel Advisors LLC purchased a new stake in Oculis in the 4th quarter worth about $389,000. XTX Topco Ltd bought a new stake in Oculis in the fourth quarter worth about $225,000. Kestra Private Wealth Services LLC bought a new position in shares of Oculis during the first quarter valued at approximately $234,000. Finally, Bank of America Corp DE raised its holdings in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after buying an additional 10,667 shares during the period. Institutional investors own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.